Cardiolipin Antibodies IgA

What the laboratory says this test is for

About 10-30% of patients continue with lingering symptoms four or more weeks after COVID-19 infection, including those who had mild, or no symptoms termed as post-COVID conditions. The Centers for Disease Control (CDC) provided Interim Guidance for Assessment and Testing for Evaluating and Caring for Patients with Post-COVID Conditions. The CDC recommends laboratory testing be guided by the patient history, physical examination, and clinical findings. Specialized tests might be considered if symptoms persist for 12 weeks post COVID. This panel is to be considered for persistent symptoms such as joint pains or rheumatological conditions.

What the laboratory says this test is for

The antiphospholipid antibody syndrome (APS) is a clinical-pathologic correlation that includes a clinical event (e.g. arterial or venous thrombosis, pregnancy morbidity) and persistent positive antiphospholipid antibodies (IgM, IgG Cardiolipin or b2GPI antibodies greater than the 99th percentile; or a lupus anticoagulant). International consensus guidelines for APS suggest waiting at least 12 weeks before retesting to confirm antibody persistence. The Systemic Lupus International Collaborating Clinics immunological classification criteria for systemic lupus erythematosus (SLE) include testing for isotype IgA, which has yet to be incorporated into APS criteria. Low level antiphospholipid antibodies may sometimes be detected in the setting of infection, drug therapy or aging.Note: Target-specific anticoagulant therapy (anti-Xa medications, direct thrombin inhibitors) may cause false positive results for Lupus anticoagulant testing but do not impact the Cardiolipin, B2GPI and Phosphatidylserine-Prothrombin antibody testing.

What the laboratory says this test is for

This panel can be helpful in the diagnosis of systemic rheumatic disorders and other autoimmune diseases. Although the test for antinuclear antibodies (ANA) is strongly associated with systemic lupus erythematosus (SLE), the laboratory evaluation for individuals with clinical suspicion of a variety of autoimmune diseases often begins with an ANA screen. This panel simultaneously tests for ANA (using immunofluorescence) as well as the important specific autoantibodies associated with a positive ANA. It also includes testing for complement proteins, rheumatoid arthritis, Sjogren's syndrome, systemic sclerosis, polymyositis, anti-phospholipid antibody syndrome, and autoimmune thyroid disease.

What the laboratory says this test is for

This assay may be useful in supporting or ruling out a diagnosis of antiphospholipid syndrome.

What the laboratory says this test is for

This profile examines the most common hereditary and acquired thrombophilia risk factors associated with recurrent miscarriage or stillbirth.